MYMD logo

MyMD Pharmaceuticals Inc

MYMD

$3.51

- $2.15 (-37.93%) This month

Closed: 22 Feb 2024 21:00 US/Eastern

Key details

CEO

Howard Yeaton

Employees

N/A

Headquarters

Baltimore, United States

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

About MyMD Pharmaceuticals Inc

mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
Finimize
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG